Myriad Genetics, Inc (MYGN) concluded trading on Wednesday at a closing price of $7.41, with 4.22 million shares of worth about $31.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.63% during that period and on April 30, 2025 the price saw a gain of about 2.92%. Currently the company’s common shares owned by public are about 91.30M shares, out of which, 88.14M shares are available for trading.
Stock saw a price change of 1.65% in past 5 days and over the past one month there was a price change of -16.46%. Year-to-date (YTD), MYGN shares are showing a performance of -45.95% which decreased to -59.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.16 but also hit the highest price of $29.30 during that period. The average intraday trading volume for Myriad Genetics, Inc shares is 1.23 million. The stock is currently trading -5.12% below its 20-day simple moving average (SMA20), while that difference is down -22.10% for SMA50 and it goes to -58.52% lower than SMA200.
Myriad Genetics, Inc (NASDAQ: MYGN) currently have 91.30M outstanding shares and institutions hold larger chunk of about 100.29% of that.
The stock has a current market capitalization of $682.99M and its 3Y-monthly beta is at 2.02. It has posted earnings per share of -$1.40 in the same period. It has Quick Ratio of 1.65 while making debt-to-equity ratio of 0.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYGN, volatility over the week remained 4.87% while standing at 6.52% over the month.
Stock’s fiscal year EPS is expected to drop by -52.92% while it is estimated to increase by 279.72% in next year.
Coverage by Piper Sandler stated Myriad Genetics, Inc (MYGN) stock as an Overweight in their note to investors on March 12, 2025, suggesting a price target of $12.50 for the stock. On February 12, 2025, Craig Hallum Initiated their recommendations, while on December 10, 2024, UBS Initiated their ratings for the stock with a price target of $18. Stock get a Market perform rating from Leerink Partners on December 09, 2024.
